Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2011:2011:456076.
doi: 10.1155/2011/456076. Epub 2011 Sep 13.

No evidence for statin-induced proteinuria in healthy volunteers as assessed by proteomic analysis

Anja Verhulst  1 , Hilde Geryl, Patrick D'Haese
Affiliations
Randomized Controlled Trial

No evidence for statin-induced proteinuria in healthy volunteers as assessed by proteomic analysis

Anja Verhulst et al. J Biomed Biotechnol. 2011.

Abstract

In clinical studies of statins (class of drugs lowering plasma cholesterol levels), transient low-molecular-weight proteinuria was observed. The causes of statin-induced proteinuria in the patient background of those studies (cardiovascular and kidney disease) are multifactorial and, therefore, a matter of debate. In light of this, it seemed interesting to investigate the effect of statins on the urinary protein concentration and proteome in healthy volunteers. Six healthy volunteers were randomly treated with rosuvastatin (40 mg/day) or pravastatin (80 mg/day) in a double-blinded cross-over study. Total urinary protein concentration and the concentration of albumin/retinol-binding protein were analysed, after which the urinary proteome was investigated. From the results described in this study, it was concluded that statins do not induce major changes in the urinary protein concentration/proteome. High variability in the baseline urinary proteome/proteins among volunteers, however, made it very difficult to find subtle (possibly isolated to individuals) effects of statins.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Schematic overview of the study setup.
Figure 2
Figure 2
Quantification of proteins (a, b), microalbuminuria (c, d), and retinol binding protein (e, f) in urine. (a, c, e): mean values (and SD) of the urinary protein content of different volunteers and different treatment periods. (b, d, f): Urinary protein content of one representative volunteer during one-treatment period.
Figure 3
Figure 3
Principal component analysis of the 36 spot maps, representing the 36 samples originating of 6 volunteers. No outlying spot maps could be identified.
Figure 4
Figure 4
Principal component analysis of “before” “during,” and “after-treatment” spot maps. No clustering of spot maps can be observed for any if the 3 conditions.
Figure 5
Figure 5
Principal component analysis of spot maps originating from different volunteers. Spot maps of the same volunteer to a certain extent cluster (ovals).
Figure 6
Figure 6
Principal component analysis of before-, during- and after-treatment spot maps of 2 different volunteers (representative examples).
Figure 7
Figure 7
Principal component analysis of “before-”, “during-” and “after-treatment” spot maps. Partial clustering (red oval) of during-treatment spot maps can be observed.
Figure 8
Figure 8
Principal component analysis of during-treatment spot maps originating from the two different statins: pravastatin (statin A) and rosuvastatin (statin B).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Tobert JA. Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors. Nature Reviews Drug Discovery. 2003;2(7):517–526. - PubMed
    1. Kovanen PT, Bilheimer DW, Goldstein JL. Regulatory role for hepatic low density lipoprotein receptors in vivo in the dog. Proceedings of the National Academy of Sciences of the United States of America. 1981;78(2):1194–1198. - PMC - PubMed
    1. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature. 1990;343(6257):425–430. - PubMed
    1. Ma P, Gil G, Sudhof TC, Bilheimer D, Goldstein J, Brown M. Mevinolin, an inhibitor of cholesterol synthesis, induces mRNA for low density lipoprotein receptor in livers of hamsters and rabbits. Proceedings of the National Academy of Sciences of the United States of America. 1986;83(21):8370–8374. - PMC - PubMed
    1. McFarlane SI, Muniyappa R, Francisco R, Sowers JR. Clinical review 145: pleiotropic effects of statins: lipid reduction and beyond. Journal of Clinical Endocrinology and Metabolism. 2002;87(4):1451–1458. - PubMed

Publication types

MeSH terms